Rising chronic diseases are driving growth in exocrine pancreatic insufficiency market
The Business Research Company’s 2026 market reports feature enhanced tools like market attractiveness analysis, TAM assessment, and company scoring matrices, along with interactive dashboards, deeper supply chain insights, and startup coverage strengthening the depth, usability, and strategic value of insights.
What Is The Estimated Market Size Of The Exocrine Pancreatic Insufficiency Market In 2026, And How Will Its Value Evolve By 2030?
The exocrine pancreatic insufficiency market has experienced significant expansion in recent years. It is projected to grow from $2.75 billion in 2025 to $2.93 billion in 2026, demonstrating a compound annual growth rate (CAGR) of 6.5%. The historical growth of this market can be attributed to the rising prevalence of chronic pancreatitis, increasing awareness surrounding digestive disorders, improved availability of enzyme therapies, the expansion of hospital pharmacy networks, and an uptick in the adoption of diagnostic testing.
The exocrine pancreatic insufficiency market is anticipated to experience significant expansion in the coming years. It is projected to reach $3.88 billion by 2030, growing at a compound annual growth rate (CAGR) of 7.3%. This projected growth can be attributed to several factors during the forecast period, including advancements in enzyme formulation technologies, an increasing geriatric population, a rising demand for homecare treatment, the proliferation of online pharmacies, and enhanced reimbursement options for digestive disorder treatments. Key trends expected in the forecast period encompass an increased adoption of pancreatic enzyme replacement therapy, a greater emphasis on early and accurate diagnosis, the development of home-based nutritional management solutions, an expansion of online pharmacy distribution networks, and improved patient awareness and educational initiatives.
Access Your Free Sample Report For In-Depth Market Analysis:
Which Major Drivers Are Influencing The Expansion Of The Exocrine Pancreatic Insufficiency Market?
The growing prevalence of chronic diseases is projected to drive the expansion of the exocrine pancreatic insufficiency market in the future. Chronic diseases are identified as long-term health conditions that continue over an extended duration, usually three months or more. The persistent nature of the primary illness can elevate the risk of secondary complications such as exocrine pancreatic insufficiency, thereby promoting enhanced management of chronic conditions via medical interventions and therapies, which can contribute to longer life spans for those affected. As an illustration, in September 2023, the World Health Organization, a specialized agency of the United Nations based in Switzerland, reported that 41 million deaths occur annually, with 74% attributed to non-communicable diseases (NCDs) or chronic diseases worldwide. Thus, the increase in chronic diseases will stimulate the growth of the exocrine pancreatic insufficiency market.
What Are The Key Segment Divisions In The Exocrine Pancreatic Insufficiency Market Segment Structure?
The exocrine pancreatic insufficiency market covered in this report is segmented –
1) By Treatment: Nutritional Management, Pancreatic Enzyme Replacement Therapy (PERT), Other Treatments
2) By Diagnosis: Imaging Tests, Computed Tomography (CT) Scan, Abdominal Ultrasound, Secretin Pancreatic Function Test, Fecal Fat Test, Fecal Elastase Test (FE-1), Other Types
3) By Symptoms: Abdominal Pain, Constipation, Diarrhea, Fatty Stools, Weight Loss, Other Symptoms
4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels
5) By End Users: Hospitals, Specialty Clinics, Homecare
Subsegments:
1) By Nutritional Management: Dietary Modifications, Nutritional Supplements
2) By Pancreatic Enzyme Replacement Therapy (PERT): Enteric-Coated Capsules, Non-Enteric-Coated Capsules, Powder Formulations
3) By Other Treatments: Medications, Surgical Interventions, Supportive Therapies
Which Trends Are Shaping The Exocrine Pancreatic Insufficiency Market?
Companies operating in the exocrine pancreatic insufficiency market are focusing on establishing patient advocacy groups, including those offering comprehensive nutritional guidance, to provide extensive nutritional advice and support. These initiatives aim to enhance awareness, education, and management of the condition among affected individuals. Comprehensive nutritional guidance represents a holistic approach that customizes dietary recommendations based on individual needs, health conditions, and lifestyle. It emphasizes education, meal planning, and sustainable practices to promote overall well-being. For instance, in June 2024, Nestlé Health Science, a Switzerland-based nutrition company, launched a GLP-1 nutrition support platform. Nestlé Health Science’s GLP-1 nutrition support platform offers tailored nutritional resources and expert guidance for individuals using GLP-1 medications, focusing on muscle preservation, gut health, and overall wellness. Its purpose is to empower users in their weight management journey by addressing unique dietary needs and fostering community support.
Which Organizations Are Engaged In The Exocrine Pancreatic Insufficiency Market?
Major companies operating in the exocrine pancreatic insufficiency market are Nestlé Health Science S.A., Nordmark Arzneimittel GmbH & Co. KG, Digestive Care Inc., Enzymedica Inc., Alcresta Therapeutics Inc., Chiesi Farmaceutici S.p.A., Amryt Pharma Plc, Pfizer Inc., F. Hoffmann-La Roche AG, AbbVie Inc., Sanofi S.A., Eli Lilly and Company, Medtronic plc, First Wave BioPharma Inc., Vivus Inc., Abbott Laboratories, Danone S.A., Fresenius SE & Co. KGaA, Baxter International Inc, Siemens Healthineers AG, Thermo Fisher Scientific Inc, GE HealthCare Technologies Inc, Koninklijke Philips N.V., Fujifilm Holdings Corporation
Get The Full Exocrine Pancreatic Insufficiency Market Report:
Which Region Is The Largest In The Exocrine Pancreatic Insufficiency Market?
North America was the largest region in the exocrine pancreatic insufficiency market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the exocrine pancreatic insufficiency market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request A Customized Exocrine Pancreatic Insufficiency Market Report For Competitive Insights:
Browse Through More Reports Similar to the Global Exocrine Pancreatic Insufficiency Market 2026, By The Business Research Company
Pancreatic Cancer Diagnostic Market Report 2026
https://www.thebusinessresearchcompany.com/report/pancreatic-cancer-diagnostic-global-market-report
Exocrine Pancreatic Insufficiency Epi Therapeutics And Diagnostics Market Report 2026
Acute Pancreatitis Market Report 2026
https://www.thebusinessresearchcompany.com/report/acute-pancreatitis-global-market-report
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
